



## FLOSEAL Hemostatic Matrix, 10 mL

### Instructions for Use

**Caution: Federal Law (United States) restricts this device to sale by or on the order of a licensed healthcare practitioner.**

### DO NOT INJECT INTRAVASCULARLY.

FLOSEAL Hemostatic Matrix, also referred to as FLOSEAL Matrix, must not be injected into blood vessels.

### Device Description:

The FLOSEAL Matrix kit consists of a bovine-derived Gelatin Matrix component, a recombinant human Thrombin component, Applicator tips, and mixing accessories. The mixing accessories include a syringe for Matrix preparation, containing 0.9% Sodium Chloride Solution and a vial adapter for needle-free reconstitution. The accessories are included to facilitate the reconstitution and mixing of the Thrombin into the Gelatin Matrix. Applicator tips are included to facilitate the delivery of FLOSEAL Matrix to the site to be treated. (For specific package contents, see Table in “How Supplied” section.)

The Gelatin Matrix consists of cross-linked gelatin granules and is provided sterile and non-pyrogenic in a disposable syringe. The Thrombin (Recombinant) is a sterile lyophilized recombinant human Thrombin (USP). The Sodium Chloride Solution is a sterile, non-pyrogenic solution.

RECOTHROM Thrombin topical (Recombinant), is a human coagulation protein produced via recombinant DNA technology from a genetically modified Chinese Hamster Ovary (CHO) cell line. RECOTHROM is identical in amino acid sequence and structurally similar to naturally occurring human thrombin. The cell line used to manufacture RECOTHROM has been tested and shown to be free of known infectious agents. The cell culture process used in the manufacture of RECOTHROM employs no additives of human or animal origin. The purification process includes solvent-detergent treatment and nano-filtration steps dedicated to viral clearance. RECOTHROM is provided as a sterile, white to off-white, preservative-free, lyophilized powder in vials for reconstitution with diluent (sterile 0.9% sodium chloride). Reconstitution with the provided diluent, as described, yields a solution containing 588 units\*/mL of recombinant thrombin for topical use. The formulated product is clear, colorless solution upon reconstitution.

For detailed information on RECOTHROM, please refer to the prescribing information.

\*The potency expressed in units is determined using a clotting assay against an internal reference standard for potency that has been calibrated against the World Health Organization (WHO) Second International Standard for Thrombin, 01/580. Therefore, a unit used herein is equivalent to an International Unit.

The manufacturing procedure for FLOSEAL Matrix includes processing steps designed to reduce the risk of viral transmission. Several steps are included in the manufacture of the Gelatin Matrix component that reduce the risk of viral transmission. The virus reduction factors (expressed as log<sub>10</sub>) for the manufacture of the Gelatin Matrix component are provided in the table below.

| Reduction Factors for Virus Removal and/or Inactivation During the Manufacture of Gelatin Matrix |  |     |
|--|--|-----|
| Manufacturing Step   | Virus Reduction Factor of Virus Tested |     |
|  | BVDV                                   | PPV |
| Base Treatment (NaOH)  | >5.4                                   | 4.0 |
| Chemical Cross-linking   | >5.0                                   | 1.1 |
| Heat Treatment   | >6.5                                   | 1.9 |

**BVDV:** Bovine viral diarrhea virus, a model for Hepatitis C virus; **PPV** Porcine parvovirus, a model for non-enveloped viruses, among those, Hepatitis A virus.

FLOSEAL Matrix is the combination of the Gelatin Matrix component and the reconstituted Thrombin (Recombinant Human) component. Thrombin must be added to the Gelatin Matrix component prior to use. FLOSEAL Matrix is biocompatible and resorbed within 6 to 8 weeks, consistent with normal wound healing. FLOSEAL Matrix is intended only for topical administration.

### Indications:

FLOSEAL Matrix is indicated in surgical procedures (other than in ophthalmic) as an adjunct to hemostasis when control of bleeding, by ligature or conventional procedures is ineffective or impractical.

### Contraindications:

- Do not inject or compress FLOSEAL Matrix into blood vessels. Do not apply FLOSEAL Matrix in the absence of active blood flow, e.g., while the vessel is clamped or bypassed, as extensive intravascular clotting and even death may result.
- To avoid a risk of allergic-anaphylactoid reaction and/or thromboembolic events, which may be life-threatening, do not inject FLOSEAL Matrix into a vessel or tissue.
- Do not administer to patients with a history of hypersensitivity to RECOTHROM thrombin, any components of RECOTHROM, or hamster proteins.
- Do not use FLOSEAL Matrix in patients with known allergies to materials of bovine origin.
- Do not use FLOSEAL Matrix in the closure of skin incisions because it may interfere with the healing of the skin edges due to mechanical interposition of gelatin.

### Warnings:

- FLOSEAL Matrix is not intended as a substitute for meticulous surgical technique and the proper application of ligatures or other conventional procedures for hemostasis. FLOSEAL Matrix is not intended to be used as a prophylactic hemostatic agent.
- As with other hemostatic agents, circumstances that result in a negative peripheral venous pressure (e.g. patient positioning) may draw material into the vascular system, potentially resulting in life-threatening thromboembolic events.
- Excess FLOSEAL Matrix (material not incorporated in the hemostatic clot) should always be removed by gentle irrigation and suctioned out of the wound. Meticulous irrigation is required when used in, around, or in proximity to foramina in bone, areas of bony confine, the spinal cord, the brain and/or cranial nerves.
- FLOSEAL Matrix swells by approximately 10-20% after product is applied and surgeons should consider its potential effect on the surrounding anatomic areas. Maximum swell volume is achieved within about 10 minutes.
- FLOSEAL Matrix should not be used in the presence of infection. FLOSEAL Matrix should be used with caution in contaminated areas of the body. If signs of infection or abscess develop where FLOSEAL Matrix has been applied, re-operation may be necessary in order to remove the infected material and allow drainage.
- The safety and effectiveness of FLOSEAL Matrix for use in ophthalmic procedures has not been established.
- FLOSEAL Matrix should not be used for controlling post-partum bleeding or menorrhagia.
- The safety and effectiveness of FLOSEAL Matrix has not been established in children under 2 years of age and pregnant women.
- Do not use air to remove residual FLOSEAL Matrix from Applicator tip.
- Hypersensitivity reactions, including anaphylaxis, may occur. RECOTHROM thrombin is produced in a genetically modified Chinese Hamster Ovary (CHO) cell line and may contain hamster or snake proteins.

### Precautions:

#### General

- For single use only. Do not re-sterilize.
- Since the Thrombin solution can be denatured by contact with solutions containing alcohol, iodine, or heavy metal ions, FLOSEAL Matrix should not be applied before the application site is cleaned to remove any antiseptics that may contain such substances.
- When placed into cavities or closed tissue spaces, gentle approximation is advised (Do not compress.).
- As with other hemostatic agents, do not aspirate FLOSEAL Matrix into extracorporeal cardiopulmonary bypass circuits or autologous blood salvage circuits. It has been demonstrated that fragments of collagen based hemostatic agents may pass through 40µm transfusion filters of blood scavenging systems.
- Do not use FLOSEAL Matrix on bone surfaces where adhesives, such as methylmethacrylate or other acrylic adhesives, will be required to attach a prosthetic device. Microfibrillar collagen has been reported to reduce the strength of methylmethacrylate adhesives used to attach prosthetic devices to bone surfaces.
- FLOSEAL Matrix should not be used for the primary treatment of coagulation disorders.
- The safety and effectiveness of the combined use of FLOSEAL Matrix with antibiotic solutions or powders has not been established.
- The safety and effectiveness for use in neurosurgical and urological procedures has not been established through randomized clinical studies.
- In urological procedures, FLOSEAL Matrix should not be left in the renal pelvis or ureters to eliminate the potential foci for calculus formation.
- Do not cut Applicator tips, as tissue injury from sharp edges may result.

### Carcinogenesis, Mutagenesis, Impairment of Fertility

- Long-term animal studies to evaluate the carcinogenic potential of FLOSEAL Matrix or studies to determine the effect of FLOSEAL Matrix on fertility have not been performed.

### Use in Pregnancy

- It is not known whether FLOSEAL Matrix can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. FLOSEAL Matrix should be administered to a pregnant woman only if clearly needed.

### **FLOSEAL Matrix Adverse Events:**

In a randomized prospective, concurrently controlled clinical trial using a formulation of FLOSEAL Matrix containing bovine Thrombin, a total of 309 patients received FLOSEAL Matrix or the Control (Gelatin Sponge + Thrombin). The most common adverse events recorded during and after the application of the hemostatic agents were anemia, atrial fibrillation, infection, and hemorrhage. The following is a complete list of adverse events reported in greater than 1% of patients that were observed in the pivotal clinical trial for the FLOSEAL Matrix group. The corresponding adverse events for the Control group are listed for comparison. None of the adverse events that occurred were judged by the surgeon to be "Probably Related" to the use of FLOSEAL Matrix.

| <b>Adverse Events Reported in Greater than 1% of Patients in the FLOSEAL Matrix Clinical Trial</b> |                       |  |
|--|-----------------------|--|
| <b>Adverse Event</b>   | <b>FLOSEAL Matrix</b> | <b>Control (Gelatin Sponge + Thrombin)</b> |
| Anemia   | 12 (8%)               | 7 (4%)                                     |
| Fibrillation Atrial  | 10 (6%)               | 8 (5%)                                     |
| Infection  | 10 (6%)               | 11 (7%)                                    |
| Hemorrhage   | 6 (4%)                | 6 (4%)                                     |
| Pneumonia  | 6 (4%)                | 2 (1%)                                     |
| Urinary Tract Infection  | 6 (4%)                | 3 (2%)                                     |
| Rash   | 5 (3%)                | 3 (2%)                                     |
| Edema  | 5 (3%)                | 1 (<1%)                                    |
| Hypotension  | 4 (3%)                | 2 (1%)                                     |
| Respiratory Distress   | 4 (3%)                | 3 (2%)                                     |
| Confusion  | 4 (3%)                | 0 (0%)                                     |
| Dural Tear   | 4 (3%)                | 4 (3%)                                     |
| Fibrillation Ventricular   | 4 (3%)                | 3 (2%)                                     |
| Arrhythmia   | 4 (3%)                | 0 (0%)                                     |
| Heart Failure Right  | 3 (2%)                | 2 (1%)                                     |
| Thrombosis Arterial  | 3 (2%)                | 8 (5%)                                     |
| Fever  | 3 (2%)                | 2 (1%)                                     |
| Atelectasis  | 3 (2%)                | 1 (<1%)                                    |
| Pleural Effusion   | 3 (2%)                | 5 (3%)                                     |

*Counts reflect number of patients in each treatment group reporting one or more adverse events that map to a Modified COSTART 5<sup>th</sup> edition body system. At each level of summarization (Adverse Event), patients are only counted once.*

Other adverse events observed in 1% or less of the FLOSEAL Matrix clinical trial patients were myocardial infarction, cellulitis, pneumothorax, pain, cerebrovascular accident, hallucination, paresthesia, bradycardia, abscess, diarrhea, urinary retention, dehiscence, skin ulcer, transfusion reaction, dyspnea, heart arrest, lung edema, back pain, ventricular tachycardia, neuropathy, acute kidney failure, kidney tubule necrosis, gastritis, nausea, nausea and vomiting, skin rash, hyperglycemia, and heel ulcer.

The following adverse events, all rated "mild", were deemed by the surgeon to be "Possibly Related" to the use of FLOSEAL Matrix: anemia (2 patients, 1%), mild post-operative bleeding (1 patient, <1%), and local inflammation (1 patient, <1%). No other adverse events were deemed by the surgeon to be related to the use of FLOSEAL Matrix.

Allergic reactions may be encountered in people who are sensitive to bovine materials.

Only the amount of FLOSEAL necessary to achieve hemostasis should be used. Excess FLOSEAL (material not incorporated in the hemostatic clot) should always be removed by gentle irrigation from the site of application. Any FLOSEAL not removed at the time of surgery may result in diagnostic imaging confusion, e.g. present itself as a (recurring) mass or a (space occupying) lesion, or may lead to a foreign body reaction with or without clinical signs and symptoms.

Erectile dysfunction has been reported when FLOSEAL was used in surgical procedures involving the cavernous nerves occasionally exposed in radical prostatectomy procedures.

### **Gelatin-Based Hemostatic Agents Adverse Events:**

- Gelatin-based hemostatic agents may serve as a nidus for infection and abscess formation and have been reported to potentiate bacterial growth.
- Excess gelatin-based hemostatic agents should always be removed by gentle irrigation from the site of application. Removal of excess is done to avoid excessive inflammatory reaction, adhesion and/or granuloma formation.
- Giant cell granulomas have been observed at implant sites when used in the brain.
- Compression of the brain and spinal cord resulting from the accumulation of sterile fluid has been observed.
- Multiple neurologic events were reported when absorbable gelatin-based hemostatic agents were used in laminectomy operations, including cauda equina syndrome, spinal stenosis, meningitis, arachnoiditis, headaches, paresthesias, pain, bladder and bowel dysfunction, and impotence.
- The use of absorbable gelatin-based hemostatic agents during the repair of dural defects associated with laminectomy and craniotomy operations has been associated with fever, infection, leg paresthesias, neck and back pain, bladder and bowel incontinence, compromised cerebrospinal fluid circulation, cauda equina syndrome, neurogenic bladder, impotence, and paresis.
- The use of absorbable gelatin-based hemostatic agents has been associated with paralysis, due to device migration into foramina in the bone around the spinal cord, and blindness, due to device migration in the orbit of the eye, during lobectomy, laminectomy and repair of a frontal skull fracture and lacerated lobe.
- Foreign body reactions, "encapsulation" of fluid, and hematoma have been observed at implant sites.
- Excessive fibrosis and prolonged fixation of a tendon have been reported when absorbable gelatin-based sponges were used in severed tendon repair.
- Toxic shock syndrome was reported in association with the use of absorbable gelatin-based hemostats in nasal surgery.
- Fever, failure of absorption, and hearing loss have been observed when absorbable hemostatic agents were used during tympanoplasty.

### **Recombinant Human Thrombin Adverse Events:**

Antibody formation to RECOTHROM occurred in <1% of patients. None of the antibodies detected neutralized native human thrombin.

### **Equivalence of Bovine and Human Thrombin:**

The performance of FLOSEAL Matrix containing human Thrombin was compared to that of original FLOSEAL Matrix (containing bovine Thrombin) in a bleeding liver square model in pigs.

Blood flow rates for the lesions created in the pig liver model were recorded at specific time points and statistically analyzed by the method of Blackwelder and Chang modified for continuous variables. This analysis demonstrates that the performance of FLOSEAL Matrix (human Thrombin) is equivalent to the performance of FLOSEAL Matrix (bovine Thrombin) with a p-value of < 0.001 at each of the time intervals.

In addition, each lesion was subjectively scored for bleeding at each time point. These data points were analyzed using the method of Blackwelder and Chang for proportions.

The results for all lesions in all animals showed FLOSEAL Matrix (human Thrombin) and FLOSEAL Matrix (bovine Thrombin) were equivalent for each of the time intervals with a p-value of 0.015.

### **Clinical Studies:**

**Study Design and Objectives:** A prospective, randomized, controlled, multi-center, multi-specialty study was conducted using a formulation of FLOSEAL Matrix containing bovine Thrombin. Three hundred and nine (309) patients were enrolled at 10 centers. The objective of the study was to evaluate the safety and effectiveness of FLOSEAL Matrix, compared to a commercially available control hemostat, Absorbable Gelatin Sponge, USP ("Gelatin Sponge") + Thrombin, in controlling intraoperative bleeding. This study was designed to show that the FLOSEAL Matrix success rate was equivalent to the success rate for the Control.

Patients undergoing surgery in cardiac, vascular or spinal/orthopedic surgical specialties were included.

Patients were randomized only after it was determined that the bleeding could not be controlled using conventional approaches (e.g. direct pressure, sutures and/or cautery)

because of their ineffectiveness or impracticality. Success at achieving hemostasis was defined as cessation of bleeding within 10 minutes following application of the agent. The primary endpoint was hemostasis success for the first treated bleeding site. A secondary endpoint was time to hemostasis for the first treated bleeding site. Although multiple bleeding sites in the same patient were treated, only the first treated bleeding site was used to determine primary effectiveness, as this was the only site that was truly randomized.

**Clinical Study Results:**

**Primary Endpoint:** The primary endpoint, cessation of bleeding within 10 minutes of the first lesion, achieved a success rate of 96% in the FLOSEAL Matrix group and 77% in the Control group. FLOSEAL Matrix and Control were shown to be equivalent using the Blackwelder and Chang test, using a  $\Delta$  (clinically significant difference) of 0.15 ( $p < 0.0001$ ). The difference between FLOSEAL Matrix and Control was also shown to be statistically significant using the Cochran-Mantel-Haenszel test ( $p < 0.001$ ). Primary endpoint data were stratified for individual surgical specialties, and the results are summarized in the table below:

| Hemostasis Within 10 Minutes – First Lesion Only (Intent-to-Treat Patients) |                |               |
|---|----------------|---------------|
| Patient Category  | FLOSEAL Matrix | Control       |
| All Patients  | 96% (149/156)  | 77% (118/153) |
| Cardiac   | 94% (45/48)    | 60% (27/45)   |
| Vascular  | 93% (40/43)    | 76% (35/46)   |
| Spinal/Orthopedic   | 98% (64/65)    | 90% (56/62)   |

In the cardiac cohort, 88 of the 93 patients (95%) underwent surgery with extracorporeal cardiopulmonary bypass. FLOSEAL Matrix was used for hemostasis prior to heparin reversal by the administration of protamine sulfate in 19 of 46 patients. Protamine sulfate reverses the anticoagulative effects of heparin. Results for hemostasis at 10 minutes for the heparinized patients in both the FLOSEAL Matrix and Control groups, before and after protamine sulfate reversal of heparin, are shown in the table below:

| Hemostasis Success at 10 Minutes Before and After Protamine Administration (Cardiac Patients Only) |                  |                 |
|--|------------------|-----------------|
| Group  | Before Protamine | After Protamine |
| FLOSEAL Matrix   | 89% (17/19)      | 96% (26/27)     |
| Control  | 36% (5/14)       | 75% (21/28)     |

The success rate for FLOSEAL Matrix did not appear to be affected by whether or not the patient had received protamine sulfate administration. This was demonstrated by the fact that the success rate for FLOSEAL Matrix before protamine sulfate administration was similar to the success rate after protamine sulfate administration whereas the Control hemostat success rate was clearly lower before protamine sulfate reversal of heparin was administered.

**Secondary Endpoint:** A secondary endpoint was time to hemostasis for the first treated bleeding site. The data for time to hemostasis are summarized in the table below.

| Cumulative Percent of Patients with Complete Hemostasis First Lesion (Protocol Valid Patients*) |                |               |
|---|----------------|---------------|
| Time Interval   | FLOSEAL Matrix | Control       |
| 0 – 1 minute  | 41% (62/153)   | 21% (32/150)  |
| 1 – 2 minutes   | 69% (106/153)  | 32% (48/150)  |
| 2 – 3 minutes   | 85% (130/153)  | 48% (72/150)  |
| 3 – 6 minutes   | 93% (143/153)  | 68% (102/150) |
| 6 – 10 minutes  | 97% (149/153)  | 77% (115/150) |

\*Six (6) patients, 3 in the FLOSEAL Matrix group and 3 in the Control group, were excluded because of protocol deviations in measuring hemostasis for the first treated bleeding site.

When the data were stratified by surgical specialty, the median times to hemostasis were shorter for the FLOSEAL Matrix group than for the Control group in all specialties. The median times are summarized in the table below.

| Time to Hemostasis First Lesion Only (Protocol Valid Lesions)   |                |                |
|---|----------------|----------------|
| Median Time to Hemostasis in minutes (95% Confidence Interval*) |                |                |
| Patient Category  | FLOSEAL Matrix | Control        |
| All Patients  | 2.0 (1.5, 2.5) | 6.0 (5.5, 6.0) |
| Cardiac   | 2.8 (2.0, 4.0) | 8.0 (6.0, 8.5) |
| Vascular  | 2.5 (2.0, 4.0) | 6.5 (4.5, 8.0) |
| Spinal/Orthopedic   | 1.5 (1.0, 1.5) | 3.0 (2.0, 4.5) |

\*Confidence interval using a Bonferroni correction.

**Use of FLOSEAL Matrix as a Hemostatic Agent for Nasal/ Sinus Bleeding:**

FLOSEAL Matrix has been used as a hemostatic agent for the control of operative and post-operative bleeding (epistaxis) during nasal/sinus surgery in 18 patients (30 application sites). Patients were followed for 24 hours following surgery and all complications and episodes of epistaxis were recorded during this period. Intraoperative bleeding stopped in 30 of 30 (100%) application sites. No intraoperative complications were reported in this group. One patient presented with epistaxis 6 hours postoperatively; this patient was treated uneventfully and released from the hospital on the first postoperative day.

**Use of FLOSEAL Matrix as a Hemostatic Agent in Cardiovascular Surgery**

FLOSEAL Matrix was tested in a prospective randomized controlled trial<sup>1</sup> in 209 patients and compared to 206 control patients treated with either oxidized regenerated cellulose SURGICEL hemostat, or purified porcine skin gelatin GELFOAM<sup>®</sup> hemostat. Patients underwent elective cardiac and/or thoracic aortic operations.

Study endpoints included rate of successful intraoperative hemostasis, time required for hemostasis (defined as operative time comprised between decannulation and closure of the sternum), overall postoperative bleeding, rate of transfusion of blood products, rate of surgical revision for bleeding, postoperative morbidity and intensive care unit stay. Patients were followed-up for 96 hours postoperatively.

In the cohort of patients having intraoperative bleeding treated with FLOSEAL Matrix (n=110), a decreased hemostasis time was observed (32.1 ± 5.4 minutes vs. 56.3 ± 8 minutes,  $p < 0.001$ ) as compared to control n=104). Furthermore a decrease in transfusion of blood products (28.2% vs. 60.6%,  $p < 0.001$ ), revision rate (4.5% vs. 13.5%,  $p = 0.04$ ) and minor complications (20.9% vs. 33.6%,  $p = 0.04$ ) was observed in the FLOSEAL Matrix group as compared to control. Minor complications were defined as either renal failure, respiratory insufficiency or inotropic support lasting more than 24 hours.

No difference in major complications (stroke, shock, sepsis or myocardial infarction) or ICU stay was observed between groups.

Reference

- Nasso G, Piancone F, Bonifazi R, et al. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery. Ann Thorac Surg 2009;88(5):1520-1526.

**How Supplied:**

FLOSEAL Matrix is provided in the configuration shown in the table below.

**Directions for Use:**

Thrombin must be added to the Gelatin Matrix prior to use.

Inspect the integrity of the contents of the FLOSEAL kit. If the packaging, syringe(s) or vial have been damaged or opened, do not use.

Do not connect the 0.9% sodium chloride syringe to gelatin syringe prior to reconstituting thrombin.

| FLOSEAL Hemostatic Matrix Kit Configuration |  |  |
|---|--|--|
| REF   | Gelatin Matrix Pouch   | Thrombin Component Pouch   |
| ADS202110 10mL Kit                          | <ul style="list-style-type: none"> <li>1 x 10 mL syringe with Gelatin Matrix</li> <li>1 x syringe for Matrix Preparation, containing 8.5 mL of 0.9% Sodium Chloride Solution</li> <li>1 x standard applicator tip</li> <li>1 x malleable applicator tip</li> </ul> | <ul style="list-style-type: none"> <li>1 x vial Thrombin (Recombinant Human), 5000 IU</li> <li>1 x Needle-free vial adaptor</li> </ul> |

### Opening the package

- Using aseptic technique, open the outer pouch containing the Thrombin components and deliver the sterile inner pouch to the sterile field. Items in this pouch will be used to reconstitute the Thrombin prior to mixing with the Gelatin Matrix. Once placed in the sterile field, the inner pouch may be opened at any time.
- Repeat the above procedure with the pouch containing the Gelatin Matrix Components and deliver the sterile inner package to the sterile field. Once placed in the sterile field, the inner package may be opened at any time.


### Preparing the Thrombin solution

- Remove the lid from the vial adapter packaging.
- Remove the cap from the Syringe for Matrix preparation, containing 0.9% Sodium Chloride Solution and discard the cap.
- While gripping the vial adapter packaging, attach the syringe to the Luer connector of the vial adapter and remove it from remaining packaging.




- Remove the plastic flip-off cap from the Thrombin vial. While holding the vial adapter / syringe assembly, pierce the rubber stopper of the Thrombin vial.

### Sodium Chloride



- Depress the plunger fully to ensure complete transfer of the sodium chloride solution into the vial.
- Loosen the syringe connection one quarter (1/4) turn to release the vacuum in the vial, then re-tighten syringe.
- Facilitate reconstitution of the Thrombin by holding the vial and gently swirling it with the syringe and vial adapter attached until the Thrombin is completely dissolved.



- Once reconstituted, the Thrombin Solution can be used to prepare FLOSEAL Matrix immediately or may be stored in the vial up to four (4) hours.
- Aspirate the Thrombin Solution to the 8 mL fill line on the syringe.



- When ready to prepare the FLOSEAL Matrix, disconnect the syringe from the vial adapter and proceed to mix with the Gelatin Matrix granules following the steps in the next section.
- Discard the remaining Thrombin solution, Thrombin vial and vial adapter appropriately.

### Mixing the Thrombin Solution into the Gelatin Matrix


- Remove and discard the Luer cap from the Gelatin Matrix Syringe, taking care to avoid spilling the Gelatin Matrix granules. Connect the two syringes.
- **Quickly** push the plunger of the **Thrombin solution syringe** to fully pass the solution into the Gelatin Matrix syringe and back again. This constitutes "one pass."
- **Rapidly** repeat this transfer for a total of 10 passes. It may take several passes for all the Gelatin Matrix granules to hydrate. Do not use excessive force to push the dry granules through the Luer connection during the first few passes as it may clog. **Ensure the syringe labeled FLOSEAL contains the FLOSEAL Matrix at the completion of mixing.**

Keep syringes connected until ready to use. Allow 30 seconds after preparation before product is applied to help ensure optimal product consistency and performance. To prevent premature drying of FLOSEAL Matrix, syringes can be kept connected until product is required.

FLOSEAL Matrix may be used up to eight (8) hours after mixing with the Thrombin solution.

When ready to use, remove the empty Thrombin solution syringe and discard appropriately. If desired, connect an Applicator tip to the FLOSEAL Matrix syringe. FLOSEAL Matrix may also be extruded directly from the syringe.

### **FLOSEAL Matrix Placement/Application Steps:**



Do not inject FLOSEAL Matrix into blood vessels. See the Contraindications, Warnings, Precautions, and Adverse Events sections contained in these Instructions for Use.

For best results, FLOSEAL Matrix should be in complete contact with the actively bleeding tissue surface.

The particles of FLOSEAL Matrix swell approximately 10-20% upon contact with blood or other fluids creating a tamponade effect. Maximum swell volume is achieved within about 10 minutes.

### Application Technique

- Identify the source of bleeding at the tissue surface. This is the target site for FLOSEAL Matrix application.
- Manually approximate a gauze sponge moistened with sterile (non-heparinized) saline against the bleeding surface and use the Applicator tip (or syringe tip) to dispense FLOSEAL Matrix between the sponge and the bleeding surface. The gauze sponge will hold FLOSEAL Matrix in place against the bleeding surface in the presence of active bleeding. Apply enough FLOSEAL Matrix to create a small "mound" of material at the source of bleeding.
- For tissue defects ("divots" or "craters"), begin applying FLOSEAL Matrix at the deepest part of the lesion, and continue applying material as the syringe (or Applicator tip, if used) is withdrawn from the lesion. This "back-filling" action will ensure that FLOSEAL Matrix comes into contact with the entire bleeding surface at the tissue defect.
- Apply a gauze sponge moistened with sterile (non-heparinized) saline to approximate the FLOSEAL Matrix against the bleeding surface, conforming it to the lesion.
- After approximately two (2) minutes, lift the gauze sponge and inspect the wound site. Once bleeding has ceased, excess FLOSEAL Matrix (not incorporated in the hemostatic clot) should always be removed by gentle irrigation and suctioned away from the treatment site.
- To minimize disruption of the clot, remove gauze sponge after hemostasis has been achieved. If the gauze sponge adheres to the newly-formed clot, irrigate the sponge with non-heparinized saline and carefully remove it from the treated site.
- In cases of persistent bleeding, indicated by saturation and bleeding through the granules, insert the Applicator tip through the center of the mass of previously placed FLOSEAL Matrix to deliver fresh FLOSEAL Matrix as close as possible to the tissue surface. After re-application of FLOSEAL Matrix, resume approximation with a gauze sponge for up to another two (2) minutes, and then inspect the site again. Repeat re-application if necessary.
- If desired, dispense residual FLOSEAL Matrix from the tip using an equivalent amount of saline. Do not use air to apply the residual FLOSEAL Matrix.
- Once bleeding has ceased, excess FLOSEAL Matrix, material not incorporated in the hemostatic clot, should always be removed by gentle irrigation and suctioned out of the wound.

- Do not disrupt the FLOSEAL Matrix clot by physical manipulation. FLOSEAL Matrix incorporated in the hemostatic clot should be left *in situ*.
- After use, properly dispose of the FLOSEAL Matrix device with tip attached (if used).

**Storage Conditions:**

The FLOSEAL Matrix kit should be stored at 2 - 25°C (36 - 77°F). **Do not freeze.**



**Baxter Healthcare Corporation**  
21026 Alexander Court  
Hayward, CA 94545, USA

**Baxter, Floseal, and Recothrom are registered trademarks of Baxter International Inc.**

**Gelfoam is a registered trademark of Pharmacia & Upjohn Company LLC, and is used under license.**

**Surgicel is a registered trademark of Johnson & Johnson**

U.S. - Customer Service 1-888-229-0001

Label Code: 0719003963

Rev. Date: 2023-04-01

| Symbols Referenced on Packaging  |  |  |
|--|--|--|
| Symbol   | Symbol Title / Description   | Standard and Symbol Number                 |
| <br><a href="http://edocs.baxter.com">http://edocs.baxter.com</a> | Consult instructions for use, eIFU indicator; Indicates the need for the user to consult the instructions for use and the instructions for use are available in an electronic format.                                    | ISO 15223-1, 5.4.3                         |
|    | Do not inject into blood vessels; Indicates a medical device that should not be injected into blood vessels.   | N/A  |
|   | Do not use if package is damaged; Indicates a medical device that should not be used if the package has been damaged or opened.  | ISO 15223-1, 5.2.8                         |
|    | Sterilized using ethylene oxide; Indicates a medical device that has been sterilized using ethylene oxide.   | ISO 15223-1, 5.2.3                         |
|    | Sterilized using irradiation; Indicates a medical device that has been sterilized using irradiation.   | ISO 15223-1, 5.2.4                         |
|   | Temperature limit; Indicates the temperature limits to which the medical device can be safely exposed.   | ISO 15223-1, 5.3.7                         |
|   | Do not re-use; Indicates a medical device that is intended for one use, or for use on a single patient during a single procedure.  | ISO 15223-1, 5.4.2                         |
|   | Catalogue number; Indicates the manufacturer's catalogue number so that the medical device can be identified.  | ISO 15223-1, 5.1.6                         |
|   | Batch code; Indicates the manufacturer's batch code so that the batch or lot can be identified.  | ISO 15223-1, 5.1.5                         |
|   | Use-by date; Indicates the date after which the medical device is not to be used.  | ISO 15223-1, 5.1.4                         |
|   | Not made with natural rubber latex; Indicates the device is not made with natural rubber latex or dry natural rubber latex as a material of construction within the medical device or the packaging of a medical device. | ISO 15223-1, 5.4.5 and Annex B, Section B2 |
|   | Single sterile barrier system with protective packaging inside   | ISO 15223-1, 5.2.13                        |